Đang chuẩn bị liên kết để tải về tài liệu:
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Castration resistant prostate cancer (CRPC) is a leading cause of cancer-related deaths in men. The primary cause of mortality and morbidity in patients is bone metastases and remodeling resulting in osteoblastic and osteolytic lesions. Recently, cabozantinib, a multi-kinase inhibitor (VEGFR2 and c-MET inhibitor), was shown to have efficacy on bone lesions in patients. |

TÀI LIỆU LIÊN QUAN

Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: An evaluation of the tyrosine kinase inhibitors axitinib and asciminib

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: A retrospective study

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: Analysis from a randomised, double-blind phase II study

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: Results of matching-adjusted indirect comparison analyses

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer